Chikungunya
CDC recommends spring COVID-19 booster shot for older adults
The CDC on Wednesday recommended a spring COVID-19 vaccine booster shot for adults aged 65 years or older.
Ace the Case: A 61-Year-Old Man Returning From International Travel With New-Onset Back and Joint Pain
There is no commercial support for this activity.
Major vaccine developments put new shots on market in 2023
Major vaccine developments in 2023 included the approvals of the first two vaccines against respiratory syncytial virus, the first chikungunya vaccine, a new vaccine against malaria, and a move to new monovalent COVID-19 vaccines.
Top in ID: Novel procedure for lung infection; leftover antibiotics threaten stewardship
The surgical team at Northwestern Medicine placed breast implants in a man’s chest cavity to hold his heart in place as he underwent a double-lung transplant following a month-long infection.
FDA approves world’s first chikungunya vaccine
The FDA approved the world’s first vaccine against chikungunya virus.
Top in ID: Long COVID study points to gut; vaccination reduces cardiovascular risks
Brain fog and other long COVID symptoms could arise from depleted serotonin triggered by persistent SARS-CoV-2 infection in the gut, supporting the study of selective serotonin reuptake inhibitors for treatment of long COVID.
Bavarian Nordic’s chikungunya vaccine candidate effective across age groups
Bavarian Nordic’s chikungunya vaccine candidate was shown to be highly immunogenic in participants across age groups, according to data presented at IDWeek.
FDA extends approval deadline for Valneva’s chikungunya vaccine by 3 months
The FDA extended the review period for Valneva’s chikungunya vaccine candidate by 3 months while the design of a phase 4 study is finalized.
VIDEO: ‘With everything else going on,’ do not forget about arboviruses
WASHINGTON — In this video interview, Karen M. Krueger, MD, assistant professor of infectious diseases at Northwestern Medicine, talks about the WHO’s Global Arbovirus Initiative, which launched earlier this year.
Chikungunya vaccine candidate highly protective in phase 3 trial, Valneva says
Valneva said Wednesday that its single-shot chikungunya vaccine candidate induced protective neutralizing antibody titers in more than 96% of patients 6 months after vaccination in a phase 3 trial.